L-Carnitine-d9 (chloride)
(Synonyms: 盐酸左卡尼汀:,(R)-Carnitine-d9 chloride; Levocarnitine-d9 chloride) 目录号 : GC52094
An internal standard for the quantification of L-carnitine
Cas No.:2687961-04-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
L-Carnitine-d9 is intended for use as an internal standard for the quantification of L-carnitine by GC- or LC-MS. L-Carnitine is a conditionally essential nutrient.1 It is obtained from dietary sources or through the metabolism of lysine and methionine.2,3 L-Carnitine facilitates the transport of long-chain fatty acids into the mitochondrial matrix for β-oxidation, has other diverse roles on metabolism, and is involved in the maintenance of coenzyme A stores. Plasma and/or tissue levels of L-carnitine are decreased in primary L-carnitine deficiency, a disorder characterized by impaired fatty acid oxidation, with symptoms varying depending on whether it is systemic or muscle-specific.1 Serum and tissue levels of L-carnitine are also reduced in secondary L-carnitine deficiencies caused by a variety of hereditary defects or acquired disorders.
1.Seim, H., Eichler, K., and Kleber, H.-P.L(-)-Carnitine and its precursor, γ-butyrobetaineNutraceuticals in Health and Disease Prevention217-256(2001) 2.Vaz, F.M., and Wanders, R.J.A.Carnitine biosynthesis in mammalsBiochem. J.361(Pt 3)417-429(2002) 3.Fu, L., Huang, M., and Chen, S.Primary carnitine deficiency and cardiomyopathyKorean. Circ. J.43(12)785-792(2013)
| Cas No. | 2687961-04-0 | SDF | Download SDF |
| 别名 | 盐酸左卡尼汀:,(R)-Carnitine-d9 chloride; Levocarnitine-d9 chloride | ||
| Canonical SMILES | [2H]C([2H])([N+](C([2H])([2H])[2H])(C[C@@H](CC(O)=O)O)C([2H])([2H])[2H])[2H].[Cl-] | ||
| 分子式 | C7H7D9NO3 • Cl | 分子量 | 206.7 |
| 溶解度 | DMF: 15 mg/ml,DMSO: 20 mg/ml,Ethanol: 25 mg/ml,PBS (pH 7.2): 10 mg/ml | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.8379 mL | 24.1896 mL | 48.3793 mL |
| 5 mM | 0.9676 mL | 4.8379 mL | 9.6759 mL |
| 10 mM | 0.4838 mL | 2.419 mL | 4.8379 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet